Elekta Obtains FDA Clearance for Automated Spot Scanning

Elekta has obtained the 510(k) approval from the U.S. Food and Drug Administration for its XiO software, which is a therapy decision software for automated spot scanning.

This proton supplying method is enabled to offer an accurate dosage to the tumor mass by means of utilizing several compact beamlets as an alternative to the single outsized beam. The automated spot scanning method enables Intensity Modulated Proton Therapy (IMPT).

Further, treatment planning platform and XiO provide another opportunity for proton treatment centers to decide proton delivery methods. XiO offers distinct tools to quickly locate spots to build ideal dosage and to develop dosage estimation algorithm for beam optimization.

Virgil Willcut, Vice President of Product Management, Physics & Research for Elekta Treatment Planning, has stated that the automated streamlining of spot dosage deliveries enables doctors to easily plan their therapy and deliver a conformed beam around the tumor, thereby avoiding the dosage to affect the nearby normal tissue. He mentioned that the spot scanning approach is significant for pediatric patients since it offers reduced neutron dosage than the traditional proton delivery methods.